paclitaxel or nab-paclitaxel or pemetrexed

The term **paclitaxel or nab-paclitaxel or pemetrexed** refers to the investigator's choice of chemotherapy agent used as part of the platinum-doublet backbone in clinical trials, specifically the Genelux Corporation Phase 2 trial for Olvi-Vec in non-small cell lung cancer (NSCLC). This grouping encompasses three distinct cytotoxic agents: **paclitaxel**, a small-molecule taxane that stabilizes microtubules to inhibit mitosis; **nab-paclitaxel** (Abraxane), a nanoparticle albumin-bound formulation of paclitaxel designed to improve solubility and tolerability; and **pemetrexed** (Alimta), a multi-targeted antifolate that disrupts DNA synthesis by inhibiting enzymes such as thymidylate synthase (TS) and dihydrofolate reductase (DHFR). In the context of the Olvi-Vec trial, one of these three agents is selected by the physician and combined with a platinum agent (carboplatin or cisplatin) to form a doublet chemotherapy backbone, which is then administered alongside the oncolytic virus Olvi-Vec and an immune checkpoint inhibitor.

Brand names

AbraxaneAlimtaTaxol

Other names

Physician's choice chemotherapy